Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.34
+31.8%
$0.24
$0.17
$3.93
$1.08M-0.09130,325 shs357 shs
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
$1.54
+2.0%
$1.54
$1.12
$3.26
N/A2.0726,647 shs14,097 shs
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$2.18
+1.1%
$2.21
$1.82
$3.09
$88.24M1.59142,022 shs18,026 shs
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
$0.00
$0.03
$0.38
$21.70MN/A52,703 shs198,200 shs
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
$0.40
$0.10
$6.74
$423.91M0.772.19 million shs161,505 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
+31.80%+41.39%+30.73%+30.63%-89.97%
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
+2.05%-0.65%-8.33%+8.45%-33.62%
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
+1.11%+0.65%-3.36%+4.00%-14.02%
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
0.00%0.00%0.00%0.00%0.00%
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
2.596 of 5 stars
0.04.00.04.62.00.01.9
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
2.5086 of 5 stars
3.55.00.00.00.61.70.0
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
0.4524 of 5 stars
0.03.00.00.01.00.80.6
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.00
N/AN/AN/A
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
3.00
Buy$6.00289.61% Upside
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
2.00
HoldN/AN/A
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
0.00
N/AN/AN/A
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ORMP, COCP, PVOTF, ATXI, and VBLT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.00 ➝ $6.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$1.92 per shareN/A
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/AN/AN/AN/A$0.94 per shareN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
$1.34M66.58N/AN/A$3.61 per share0.60
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/AN/AN/AN/A$0.01 per shareN/A
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
$660K0.00N/AN/A$0.32 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M$18.350.02N/AN/A-471.57%-296.50%8/7/2025 (Estimated)
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
-$17.50M-$1.57N/AN/AN/AN/A-135.12%-102.38%8/13/2025 (Estimated)
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$19.06M-$0.44N/AN/AN/AN/A-11.34%-10.73%8/13/2025 (Estimated)
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/A
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
-$32.30M-$0.21N/AN/AN/AN/A-73.45%-54.11%N/A

Latest ORMP, COCP, PVOTF, ATXI, and VBLT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
-$0.52-$0.23+$0.29-$0.23N/AN/A
5/15/2025Q1 2025
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
-$0.03-$0.19-$0.16-$0.19N/A$2.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/AN/AN/AN/AN/A
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/AN/AN/AN/AN/A
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/AN/AN/AN/AN/A
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
2.70
2.70
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/A
4.57
4.57
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
N/A
23.94
23.94
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/A
3.62
3.62
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
N/A
4.63
4.63
CompanyEmployeesShares OutstandingFree FloatOptionable
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
43.18 million2.02 millionNot Optionable
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
10N/AN/ANot Optionable
Oramed Pharmaceuticals Inc. stock logo
ORMP
Oramed Pharmaceuticals
1040.85 million35.25 millionOptionable
BetterLife Pharma Inc. stock logo
PVOTF
BetterLife Pharma
N/A171.41 millionN/ANot Optionable
Vascular Biogenics Ltd. stock logo
VBLT
Vascular Biogenics
777.64 million72.88 millionOptionable

Recent News About These Companies

AlboGraft Polyester Vascular Graft from LeMaitre
Tommy Garten elected to VBL Hall of Fame
Vascular News and Research
Notable Labs Closes Merger Transaction With VBL Therapeutics
Vascular Biogenics Rises on Presentation Hype

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avenue Therapeutics stock logo

Avenue Therapeutics NASDAQ:ATXI

$0.34 +0.08 (+31.80%)
As of 07/3/2025 11:23 AM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Cocrystal Pharma stock logo

Cocrystal Pharma NASDAQ:COCP

$1.54 +0.03 (+1.99%)
As of 07/3/2025 01:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Oramed Pharmaceuticals stock logo

Oramed Pharmaceuticals NASDAQ:ORMP

$2.18 +0.02 (+1.11%)
Closing price 07/3/2025 01:10 PM Eastern
Extended Trading
$2.18 0.00 (-0.14%)
As of 07/3/2025 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

BetterLife Pharma stock logo

BetterLife Pharma OTCMKTS:PVOTF

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.

Vascular Biogenics stock logo

Vascular Biogenics NASDAQ:VBLT

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.